» Articles » PMID: 33843470

A Role for GLUT3 in Glioblastoma Cell Invasion That is Not Recapitulated by GLUT1

Abstract

The multifaceted roles of metabolism in invasion have been investigated across many cancers. The brain tumor glioblastoma (GBM) is a highly invasive and metabolically plastic tumor with an inevitable recurrence. The neuronal glucose transporter 3 (GLUT3) was previously reported to correlate with poor glioma patient survival and be upregulated in GBM cells to promote therapeutic resistance and survival under restricted glucose conditions. It has been suggested that the increased glucose uptake mediated by GLUT3 elevation promotes survival of circulating tumor cells to facilitate metastasis. Here we suggest a more direct role for GLUT3 in promoting invasion that is not dependent upon changes in cell survival or metabolism. Analysis of glioma datasets demonstrated that GLUT3, but not GLUT1, expression was elevated in invasive disease. In human xenograft derived GBM cells, GLUT3, but not GLUT1, elevation significantly increased invasion in transwell assays, but not growth or migration. Further, there were no changes in glycolytic metabolism that correlated with invasive phenotypes. We identified the GLUT3 C-terminus as mediating invasion: substituting the C-terminus of GLUT1 for that of GLUT3 reduced invasion. RNA-seq analysis indicated changes in extracellular matrix organization in GLUT3 overexpressing cells, including upregulation of osteopontin. Together, our data suggest a role for GLUT3 in increasing tumor cell invasion that is not recapitulated by GLUT1, is separate from its role in metabolism and survival as a glucose transporter, and is likely broadly applicable since GLUT3 expression correlates with metastasis in many solid tumors.

Citing Articles

Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.


Targeting glycolysis: exploring a new frontier in glioblastoma therapy.

Yang L, Li S, Yu L, Leng J, Li N Front Immunol. 2025; 15:1522392.

PMID: 39877360 PMC: 11772265. DOI: 10.3389/fimmu.2024.1522392.


The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.

Du J, Shen M, Chen J, Yan H, Xu Z, Yang X Front Pharmacol. 2025; 15():1510080.

PMID: 39850557 PMC: 11754210. DOI: 10.3389/fphar.2024.1510080.


Mild-Temperature Catalyzed Hydrosilylation for Simplified Carbohydrate Functionalization of Porous Silicon Nanoparticles.

Nolli M, Terracciano M, Rea I, DErrico S, Placido Mineo G, De Stefano L Chemistry. 2024; 31(2):e202402818.

PMID: 39679769 PMC: 11724234. DOI: 10.1002/chem.202402818.


Nitric oxide has diverse effects on head and neck cancer cell proliferation and glycolysis.

Kokilakanit P, Koontongkaew S, Utispan K Biomed Rep. 2024; 21(1):106.

PMID: 38868526 PMC: 11168032. DOI: 10.3892/br.2024.1794.


References
1.
Madhavan S, Zenklusen J, Kotliarov Y, Sahni H, Fine H, Buetow K . Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res. 2009; 7(2):157-67. PMC: 2645472. DOI: 10.1158/1541-7786.MCR-08-0435. View

2.
Boyd N, Walker K, Fried J, Hackney J, McDonald P, Benavides G . Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017; 2(24). PMC: 5752277. DOI: 10.1172/jci.insight.92928. View

3.
Gao H, Hao Y, Zhou X, Li H, Liu F, Zhu H . Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncol Lett. 2019; 19(1):691-699. PMC: 6924203. DOI: 10.3892/ol.2019.11191. View

4.
Lu S, Wang Y . Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Commun (Lond). 2018; 38(1):63. PMC: 6235390. DOI: 10.1186/s40880-018-0336-6. View

5.
Ye F, Zhang Y, Liu Y, Yamada K, Tso J, Menjivar J . Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 2013; 8(11):e80397. PMC: 3832364. DOI: 10.1371/journal.pone.0080397. View